Frame the decision
Clarify the biological question, development milestone, risk, and evidence threshold before experiments begin.
Preclinical strategy • NAMs • Decision intelligence
Accelerate Drug Discovery.
De-Risk Preclinical Development.
Driven by AI & Human-Relevant Models (NAMs).
The challenge
Human biology is complex. Your preclinical plan should make it clearer.
Early decisions shape every drug development program. Yet choosing the right models, generating translational evidence, and integrating fast-moving technologies can create costly uncertainty for lean biotechnology teams.
- Select fit-for-purpose disease models and NAMs platforms
- Build reproducible studies around meaningful milestones
- Integrate experimental, clinical, and real-world evidence
- Make confident go/no-go decisions with limited resources
Our approach
From biological complexity to decision-ready evidence.
We combine deep experimental expertise with quantitative thinking to connect each study to the decision it needs to support.
Design the evidence
Select fit-for-purpose models, assays, workflows, partners, and analytical methods around context of use.
Translate the signal
Integrate experimental and clinical data into clear recommendations, priorities, and development pathways.
How we help
Scientific depth focused on your next critical decision.
Founder-led expertise
Biology, translation, and data—under one strategic lens.
Algomira is led by Ankita Roy, Ph.D., a translational scientist and strategic advisor with more than two decades of experience across academia, biotechnology, and pharmaceutical R&D.
Meet the founder →Start a conversation
Ready to strengthen your preclinical strategy?
Schedule a complimentary 30-minute consultation to discuss your scientific challenge and identify opportunities to reduce development risk.
Schedule a discovery call